Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • More than 800 mRCC patients received sunitinib for between 2 and 6 yr without experiencing new or more severe treatment-related toxicity. Clinicians may be able to prescribe chronic sunitinib treatment for as long as patients continue to derive clinical benefit, without untoward additional risk.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5032140

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2015.07.006

PubMed ID

  • 26215605

Additional Document Info

start page

  • 345

end page

  • 51

volume

  • 69

number

  • 2